Active Biotechs rights issue substantially oversubscribed Active Biotech's rights issue of approximately 256 million SEK, with pre-emptive rights for the company's shareholders, has been completed. A count has shown that the issue is oversubscribed by 71 percent; 99.4 percent of the shares offered were subscribed for with the support of subscription rights. [more...]
